SCHEMBL2020205

SCHEMBL2020205

O=C1C=CC=C2N=CN=C12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2475313 0.98
SCHEMBL2053934 0.75
SCHEMBL2291982 0.74 KDM4E (0.30)
SCHEMBL11353633 0.67
SCHEMBL1274829 0.65
SCHEMBL959308 0.65
SCHEMBL10365025 0.64
SCHEMBL2357161 0.62
SCHEMBL3519958 0.62
SCHEMBL28980646 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212634-A1 COMPOUNDS AND METHODS TO SUPPRESS AUTOIMMUNE RESPONSE OREGON STATE UNIVERSITY (US) 2017-09-06 EP claimed
WO-2016069780-A1 COMPOUNDS AND METHODS TO SUPPRESS AUTOIMMUNE RESPONSE OREGON STATE UNIVERSITY (US) 2016-05-06 WO claimed
EP-4634169-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF Pfizer Inc. (US) 2025-10-22 EP disclosed
WO-2024127297-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF PFIZER INC. (US) 2024-06-20 WO disclosed
EP-3212634-A1 COMPOUNDS AND METHODS TO SUPPRESS AUTOIMMUNE RESPONSE OREGON STATE UNIVERSITY (US) 2017-09-06 EP disclosed
CN-103517902-B Methods and compositions for treating beta-thalassemia and sickle disease 中央研究院 2016-09-21 CN disclosed
WO-2016069780-A1 COMPOUNDS AND METHODS TO SUPPRESS AUTOIMMUNE RESPONSE OREGON STATE UNIVERSITY (US) 2016-05-06 WO disclosed
US-20130109817-A1 Modified Polymers for Delivery of Polynucleotides, Method of Manufacture, and Methods of Use Thereof MERSANA THERAPEUTICS, INC. (US) 2013-05-02 US disclosed
EP-2553019-A1 MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF Mersana Therapeutics, Inc. (US) 2013-02-06 EP disclosed
US-8349308-B2 Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof MERSANA THERAPEUTICS, INC. (US) 2013-01-08 US disclosed
US-8343977-B2 Substituted triazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8329705-B2 Substituted triazolo-pyrazine compounds ARQULE, INC. (US) 2012-12-11 US disclosed
US-20110243880-A1 MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF MERSANA THERAPEUTICS, INC. (US) 2011-10-06 US disclosed
WO-2011120053-A1 MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF MERSANA THERAPEUTICS, INC. (US) 2011-09-29 WO disclosed
WO-2011082267-A2 SUBSTITUTED TRIAZOLO-PYRAZINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
WO-2011082271-A2 SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160226-A1 Substituted Triazolo-Pyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160215-A1 Substituted Triazolo-Pyrazine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed